https://inhibrx.investorroom.com/ https://inhibrx.investorroom.com/2026-06-15-Inhibrx-Announces-U-S-FDA-Acceptance-of-BLA-for-Ozekibart-in-Patients-with-Conventional-Chondrosarcoma Mon, 15 Jun 2026 09:15:00 -0400 https://inhibrx.investorroom.com/2026-06-15-Inhibrx-Announces-U-S-FDA-Acceptance-of-BLA-for-Ozekibart-in-Patients-with-Conventional-Chondrosarcoma https://inhibrx.investorroom.com/2026-05-14-Inhibrx-Reports-First-Quarter-2026-Financial-Results Thu, 14 May 2026 16:02:00 -0400 https://inhibrx.investorroom.com/2026-05-14-Inhibrx-Reports-First-Quarter-2026-Financial-Results https://inhibrx.investorroom.com/2026-05-11-Inhibrx-Reports-Interim-Phase-2-Data-for-INBRX-106-in-First-Line-HNSCC-Initial-Results-Demonstrate-Potential-Costimulatory-Benefit-Over-PD-1-Monotherapy Mon, 11 May 2026 08:00:00 -0400 https://inhibrx.investorroom.com/2026-05-11-Inhibrx-Reports-Interim-Phase-2-Data-for-INBRX-106-in-First-Line-HNSCC-Initial-Results-Demonstrate-Potential-Costimulatory-Benefit-Over-PD-1-Monotherapy https://inhibrx.investorroom.com/2026-05-08-Inhibrx-To-Host-Webcast-Presentation-to-Provide-Clinical-Update-on-INBRX-106-HexAgon-Study-in-First-Line-HNSCC Fri, 08 May 2026 16:00:00 -0400 https://inhibrx.investorroom.com/2026-05-08-Inhibrx-To-Host-Webcast-Presentation-to-Provide-Clinical-Update-on-INBRX-106-HexAgon-Study-in-First-Line-HNSCC https://inhibrx.investorroom.com/2026-04-21-Inhibrx-Provides-Clinical-Update-on-Ozekibart-INBRX-109-in-Late-Line-Colorectal-Cancer Tue, 21 Apr 2026 16:05:00 -0400 https://inhibrx.investorroom.com/2026-04-21-Inhibrx-Provides-Clinical-Update-on-Ozekibart-INBRX-109-in-Late-Line-Colorectal-Cancer